| Literature DB >> 25747455 |
Urszula Posadowska1, Martin Parizek2, Elena Filova3, Malgorzata Wlodarczyk-Biegun4, Marleen Kamperman5, Lucie Bacakova6, Elzbieta Pamula7.
Abstract
Systemic administration of bisphosphonates, e.g. sodium alendronate (Aln) is characterized by extremely low bioavailability and high toxicity. To omit aforementioned drawbacks an injectable system for the intra-bone delivery of Aln based on Aln-loaded nanoparticles (NPs-Aln) suspended in a hydrogel matrix (gellan gum, GG) was developed. Aln was encapsulated in poly(lactide-co-glycolide) (PLGA 85:15) by solid-oil-water emulsification. Drug release tests showed that within 25 days all the encapsulated drug was released from NPs-Aln and the release rate was highest at the beginning and decreased with time. In contrast, by suspending NPs-Aln in a GG matrix, the release rate was significantly lower and more constant in time. The GG-NPs-Aln system was engineered to be easily injectable and was able to reassemble its structure after extrusion as shown by rheological measurements. Invitro studies showed that the GG-NPs-Aln was cytocompatible with MG-63 osteoblast-like cells and it inhibited RANKL-mediated osteoclastic differentiation of RAW 264.7 cells. The injectability, the sustained local delivery of small doses of Aln and the biological activity render the GG-NPs-Aln system promising for the local treatment of osteoporosis and other bone tissue disorders.Entities:
Keywords: Gellan gum; Injectability; Nanoparticles; Osteoporosis; PLGA; Sodium alendronate
Mesh:
Substances:
Year: 2015 PMID: 25747455 DOI: 10.1016/j.ijpharm.2015.03.003
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875